Related Experiment Videos
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease
1Department of Microbiology and Immunology, Virginia Commonwealth University, School of Medicine, 1101 E. Marshall Street, Richmond, Virginia 23298-0678 USA. gacabral@vcu.edu
Endocrine, Metabolic & Immune Disorders Drug Targets
|September 11, 2008
Summary
Cannabinoids, compounds that interact with cannabinoid receptors (CB1 and CB2), show potential for treating neuroinflammatory disorders. Their ability to cross the blood-brain barrier and target immune cells offers therapeutic possibilities.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Cannabinoids modulate immune cell activity in vitro and in vivo.
- Neuroinflammation is a key component in various neuropathological disorders.
- Cannabinoids possess properties suitable for brain-targeted therapies, including lipophilicity and low toxicity.
Purpose of the Study:
- To explore the therapeutic potential of cannabinoids for neuroinflammatory conditions.
- To investigate the role of cannabinoid receptors CB1 and CB2 in neuroinflammation.
Main Methods:
- Review of existing literature on cannabinoid pharmacology and neuroinflammation.
- Analysis of cannabinoid receptor expression patterns, particularly CB2 on microglia.
Main Results:
- Cannabinoid receptors CB1 and CB2 are identified, with CB1 constitutively expressed in the CNS and CB2 induced during inflammation.
- CB2 receptor expression is inducible on microglia, the brain's resident immune cells.
Conclusions:
- The cannabinoid-cannabinoid receptor system presents a potential therapeutic target for neuroinflammatory diseases.
- Targeting this system may offer a strategy for managing conditions like Alzheimer's disease, multiple sclerosis, and HIV encephalitis.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...